Hires Army Veteran to Lead It
COSTA MESA, Calif., March 24 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced it has hired Army Reserve officer Kirk Harrington, a Special Operations Force field-grade officer, diplomat, and government advisor as head of its newly-established warfighter division.
Harrington is an 18-year army veteran who in 2006 was appointed by the United States Department of State as a senior adviser to the Government of Iraq. As the sole diplomat to the Iraqi Ministries of Transportation and Construction and Housing, he oversaw every facet of Iraqi reconstruction efforts to include new implementation of roads and bridges, ports, airfields and railroads. His background includes lecturing on Middle Eastern affairs at the
The new warfighter division is a result of the Purple Heart Injury Laboratory (PHIL) initiative between the company and
"Kirk's role will be to connect the company with military research efforts and help us with sources of government funding for the military-related applications of Oxycyte(R) such as blast-related TBI, decompression sickness, and wound treatment. It's my expectation that Kirk's efforts will be more than self-supporting and that this division will become an important revenue generator for the company," said Chris J. Stern, company chairman and CEO. "He has outstanding contacts in the Department of Defense and other parts of the federal government along with a disciplined approach to getting things done. I'm looking forward to Kirk putting those assets to work in helping the company with its product development plans."
"I know only too well about the devastating effects of blast-related TBI and other wounds suffered by our military personnel. I believe Oxycyte can help them have a better and faster recovery and I want to help make it available as fast as possible. I'm excited about being a part of this with Oxygen Biotherapeutics," said Harrington.
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis pain, trauma, wound care, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, and diabetes. More information is available at www.oxybiomed.com.
Caution Regarding Forward-Looking Statements
This news release contains certain forward-looking statements by Oxygen Biotherapeutics, Inc. that involve risks and uncertainties and reflect the company's judgment as of the date of this release. These statements include those referring to the expectations for the company's new Warfighter Division and the role of the employee hired to lead it. Actual events or results may differ from Oxygen Biotherapeutics, Inc.'s expectations. There can be no assurance that the new employee will have any success in generating funding for the company from any U. S. Government source, that the new division will be financially self-supporting, or that it will generate any meaningful revenue for the company. Additional information concerning these and other risk factors affecting Oxygen Biotherapeutics, Inc.'s business can be found in the company's public periodic filings with the Securities and Exchange Commission, which are available via www.oxybiomed.com. Oxygen Biotherapeutics, Inc. disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
|SOURCE Oxygen Biotherapeutics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved